Keyphrases
Nonalcoholic Steatohepatitis
100%
Insulin Sensitizers
100%
Insulin Resistance
42%
Non-alcoholic Fatty Liver Disease (NAFLD)
28%
Pathophysiology
14%
Central Obesity
14%
Liver Transplantation
14%
Cirrhosis
14%
Metabolic Syndrome
14%
Pharmacologic
14%
Mechanism of Action
14%
Cardiovascular Risk
14%
Clinical Data
14%
Insulin Sensitivity
14%
Dyslipidemia
14%
A1 Receptor
14%
Obesity-related Hypertension
14%
Receptor Agonist
14%
Lifestyle Modification
14%
Hepatic Manifestations
14%
Dipeptidyl peptidase-4 (DPP-4)
14%
Obesity Resistance
14%
Biguanides
14%
Thiazolidinediones
14%
Clinical Review
14%
Glucagon-like
14%
Incretin
14%
Compensated Advanced Chronic Liver Disease (cACLD)
14%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Insulin Sensitizing Agent
100%
Insulin Resistance
33%
Cardiovascular Disease
11%
Dyslipidemia
11%
Metabolic Syndrome
11%
Pathophysiology
11%
Insulin Sensitivity
11%
Liver Cirrhosis
11%
Lifestyle Modification
11%
Liver Transplantation
11%
Glucagon-Like Peptide-1 Agonist
11%
Thiazolidinedione
11%
Decompensated Liver Cirrhosis
11%
Dipeptidyl Peptidase-4 Inhibitor
11%
Biguanide Derivative
11%
Incretin
11%
Diseases
11%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Insulin Sensitizing Agent
100%
Insulin Resistance
33%
Liver Cirrhosis
11%
Metabolic Syndrome X
11%
Glucagon Like Peptide 1 Receptor Agonist
11%
Thiazolidinedione
11%
Decompensated Liver Cirrhosis
11%
Dipeptidyl Peptidase IV Inhibitor
11%
Biguanide Derivative
11%
Pathophysiology
11%
Dyslipidemia
11%
Incretin
11%
Cardiovascular Disease
11%
Diseases
11%